Cargando…
Fanconi Anemia Pathway Activation by FOXM1 is Critical to Bladder Cancer Recurrence and Anticancer Drug Resistance
Although the 5-year survival rate of patients diagnosed with nonmuscle invasive bladder cancer (NMIBC) has reached 85%, more than 50% of patients suffer from frequent recurrences. To identify molecular targets associated with recurrence of NMIBC, we analyzed gene expression data and found that FOXM1...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352315/ https://www.ncbi.nlm.nih.gov/pubmed/32486251 http://dx.doi.org/10.3390/cancers12061417 |
_version_ | 1783557609121382400 |
---|---|
author | Roh, Yun-Gil Mun, Jeong-Yeon Kim, Seon-Kyu Park, Won Young Jeong, Mi-So Kim, Tae Nam Kim, Won-Tae Choi, Yung Hyun Chu, In-Sun Leem, Sun-Hee |
author_facet | Roh, Yun-Gil Mun, Jeong-Yeon Kim, Seon-Kyu Park, Won Young Jeong, Mi-So Kim, Tae Nam Kim, Won-Tae Choi, Yung Hyun Chu, In-Sun Leem, Sun-Hee |
author_sort | Roh, Yun-Gil |
collection | PubMed |
description | Although the 5-year survival rate of patients diagnosed with nonmuscle invasive bladder cancer (NMIBC) has reached 85%, more than 50% of patients suffer from frequent recurrences. To identify molecular targets associated with recurrence of NMIBC, we analyzed gene expression data and found that FOXM1 and FANCD2 were involved in recurrence. Therefore, we investigated how these genes were involved in the mechanism of recurrence and confirmed their usefulness as biomarkers. Investigation have shown that FOXM1 directly regulated the transcription of FANCD2, which is the key gene of the Fanconi anemia (FA) pathway. Depletion of FOXM1 resulted in DNA repair defects in the FA pathway and in decreased resistance to chemotherapy. Thus, the FANCD2-associated FA pathway activated by FOXM1 is an important mechanism involved in chemotherapy-related recurrence. In conclusion, FOXM1 and FANCD2 can be used as prognostic factors that are associated with high risk of recurrence and with anticancer drug resistance properties in NMIBC patients. |
format | Online Article Text |
id | pubmed-7352315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73523152020-07-21 Fanconi Anemia Pathway Activation by FOXM1 is Critical to Bladder Cancer Recurrence and Anticancer Drug Resistance Roh, Yun-Gil Mun, Jeong-Yeon Kim, Seon-Kyu Park, Won Young Jeong, Mi-So Kim, Tae Nam Kim, Won-Tae Choi, Yung Hyun Chu, In-Sun Leem, Sun-Hee Cancers (Basel) Article Although the 5-year survival rate of patients diagnosed with nonmuscle invasive bladder cancer (NMIBC) has reached 85%, more than 50% of patients suffer from frequent recurrences. To identify molecular targets associated with recurrence of NMIBC, we analyzed gene expression data and found that FOXM1 and FANCD2 were involved in recurrence. Therefore, we investigated how these genes were involved in the mechanism of recurrence and confirmed their usefulness as biomarkers. Investigation have shown that FOXM1 directly regulated the transcription of FANCD2, which is the key gene of the Fanconi anemia (FA) pathway. Depletion of FOXM1 resulted in DNA repair defects in the FA pathway and in decreased resistance to chemotherapy. Thus, the FANCD2-associated FA pathway activated by FOXM1 is an important mechanism involved in chemotherapy-related recurrence. In conclusion, FOXM1 and FANCD2 can be used as prognostic factors that are associated with high risk of recurrence and with anticancer drug resistance properties in NMIBC patients. MDPI 2020-05-30 /pmc/articles/PMC7352315/ /pubmed/32486251 http://dx.doi.org/10.3390/cancers12061417 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Roh, Yun-Gil Mun, Jeong-Yeon Kim, Seon-Kyu Park, Won Young Jeong, Mi-So Kim, Tae Nam Kim, Won-Tae Choi, Yung Hyun Chu, In-Sun Leem, Sun-Hee Fanconi Anemia Pathway Activation by FOXM1 is Critical to Bladder Cancer Recurrence and Anticancer Drug Resistance |
title | Fanconi Anemia Pathway Activation by FOXM1 is Critical to Bladder Cancer Recurrence and Anticancer Drug Resistance |
title_full | Fanconi Anemia Pathway Activation by FOXM1 is Critical to Bladder Cancer Recurrence and Anticancer Drug Resistance |
title_fullStr | Fanconi Anemia Pathway Activation by FOXM1 is Critical to Bladder Cancer Recurrence and Anticancer Drug Resistance |
title_full_unstemmed | Fanconi Anemia Pathway Activation by FOXM1 is Critical to Bladder Cancer Recurrence and Anticancer Drug Resistance |
title_short | Fanconi Anemia Pathway Activation by FOXM1 is Critical to Bladder Cancer Recurrence and Anticancer Drug Resistance |
title_sort | fanconi anemia pathway activation by foxm1 is critical to bladder cancer recurrence and anticancer drug resistance |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352315/ https://www.ncbi.nlm.nih.gov/pubmed/32486251 http://dx.doi.org/10.3390/cancers12061417 |
work_keys_str_mv | AT rohyungil fanconianemiapathwayactivationbyfoxm1iscriticaltobladdercancerrecurrenceandanticancerdrugresistance AT munjeongyeon fanconianemiapathwayactivationbyfoxm1iscriticaltobladdercancerrecurrenceandanticancerdrugresistance AT kimseonkyu fanconianemiapathwayactivationbyfoxm1iscriticaltobladdercancerrecurrenceandanticancerdrugresistance AT parkwonyoung fanconianemiapathwayactivationbyfoxm1iscriticaltobladdercancerrecurrenceandanticancerdrugresistance AT jeongmiso fanconianemiapathwayactivationbyfoxm1iscriticaltobladdercancerrecurrenceandanticancerdrugresistance AT kimtaenam fanconianemiapathwayactivationbyfoxm1iscriticaltobladdercancerrecurrenceandanticancerdrugresistance AT kimwontae fanconianemiapathwayactivationbyfoxm1iscriticaltobladdercancerrecurrenceandanticancerdrugresistance AT choiyunghyun fanconianemiapathwayactivationbyfoxm1iscriticaltobladdercancerrecurrenceandanticancerdrugresistance AT chuinsun fanconianemiapathwayactivationbyfoxm1iscriticaltobladdercancerrecurrenceandanticancerdrugresistance AT leemsunhee fanconianemiapathwayactivationbyfoxm1iscriticaltobladdercancerrecurrenceandanticancerdrugresistance |